Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for weight management in pediatric Prader-Willi syndrome
NL-OMON47321Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jun 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of liraglutide in obesity, Prader-Willi syndrome (PWS), sponsored by Novo Nordisk. Started Jun 2016; status: active, not recruiting.
02
Drugs
03
Conditions
obesityPrader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NL-OMON47321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47321.